Maurício Ressurreição, de Sousa Gracinda, Seghatchian Jerard
Lisbon Regional Blood Centre, Portuguese Blood Institute, Parque da Saúde, Av. Brasil, No. 53 Pav. 17, 1749-005 Lisboa, Portugal.
Transfus Apher Sci. 2005 Nov;33(3):351-6. doi: 10.1016/j.transci.2005.08.005. Epub 2005 Oct 14.
The current status of potential adverse reactions associated with the use of apheresis technology is reviewed, focussing on three main areas: adverse events related to component collection, progenitor cells collection and therapeutic apheresis. Based on available information it is believed that apheresis technologies are safe and increasingly used in transfusion medicine, including in auto-transfusion and different types of therapy. Occasionally, however, for various donor/patient and operational reasons, mild or moderate adverse reactions do occur. The majority of these reactions are related to vascular access and anticoagulants used, which can be mostly eliminated with calcium/magnesium administration. The reactions associated with therapeutic apheresis are more frequent (6.75%) than the multi-components and stem cell collections. Most of these reactions are generally mild and only 0.89% has been classified as severe. A national registry of donor adverse reactions as well as a planned haemovigilance system may prove helpful in identifying the potential causes which might be associated with either to donor/donation and/or with a particular technology or procedure.
本文综述了与血液分离技术使用相关的潜在不良反应的现状，重点关注三个主要方面：与成分采集、祖细胞采集和治疗性血液分离相关的不良事件。根据现有信息，认为血液分离技术是安全的，并且在输血医学中越来越多地使用，包括自体输血和不同类型的治疗。然而，偶尔由于各种供体/患者和操作原因，确实会发生轻度或中度不良反应。这些反应大多数与血管通路和使用的抗凝剂有关，通过给予钙/镁大多可以消除。与治疗性血液分离相关的反应比多成分和干细胞采集更频繁（6.75%）。这些反应大多数通常是轻度的，只有0.89%被归类为严重反应。一个全国性的供体不良反应登记系统以及一个计划中的血液监测系统可能有助于识别可能与供体/献血和/或特定技术或程序相关的潜在原因。
